TCRX Annual CFF
$135.44 M
+$106.09 M+361.38%
31 December 2023
Summary:
As of January 23, 2025, TCRX annual cash flow from financing activities is $135.44 million, with the most recent change of +$106.09 million (+361.38%) on December 31, 2023. During the last 3 years, it has risen by +$135.16 million (+46928.82%). TCRX annual CFF is now -28.59% below its all-time high of $189.67 million, reached on December 31, 2021.TCRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRX Quarterly CFF
$1.23 M
-$160.36 M-99.24%
30 September 2024
Summary:
As of January 23, 2025, TCRX quarterly cash flow from financing activities is $1.23 million, with the most recent change of -$160.36 million (-99.24%) on September 30, 2024. Over the past year, it has increased by +$1.48 million (+588.10%). TCRX quarterly CFF is now -99.24% below its all-time high of $161.59 million, reached on June 30, 2024.TCRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRX TTM CFF
$163.09 M
+$1.48 M+0.92%
30 September 2024
Summary:
As of January 23, 2025, TCRX TTM cash flow from financing activities is $163.09 million, with the most recent change of +$1.48 million (+0.92%) on September 30, 2024. Over the past year, it has increased by +$27.56 million (+20.34%). TCRX TTM CFF is now -14.01% below its all-time high of $189.67 million, reached on December 31, 2021.TCRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +361.4% | +588.1% | +20.3% |
| 3 y3 years | +10000.0% | +588.1% | +20.3% |
| 5 y5 years | +289.1% | +588.1% | +20.3% |
TCRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -28.6% | +361.4% | -99.2% | +588.1% | -14.0% | +457.2% |
| 5 y | 5-year | -28.6% | >+9999.0% | -99.2% | +279.3% | -14.0% | >+9999.0% |
| alltime | all time | -28.6% | >+9999.0% | -99.2% | +279.3% | -14.0% | >+9999.0% |
TScan Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.23 M(-99.2%) | $163.09 M(+0.9%) |
| June 2024 | - | $161.59 M(>+9900.0%) | $161.61 M(+19.1%) |
| Mar 2024 | - | $258.00 K(+1257.9%) | $135.70 M(+0.2%) |
| Dec 2023 | $135.44 M(+361.4%) | $19.00 K(-107.5%) | $135.44 M(-0.1%) |
| Sept 2023 | - | -$252.00 K(-100.2%) | $135.53 M(-17.8%) |
| June 2023 | - | $135.68 M(>+9900.0%) | $164.91 M(+463.5%) |
| Mar 2023 | - | $0.00(-100.0%) | $29.27 M(-0.3%) |
| Dec 2022 | $29.36 M | $108.00 K(-99.6%) | $29.36 M(-0.0%) |
| Sept 2022 | - | $29.13 M(>+9900.0%) | $29.37 M(-67.7%) |
| June 2022 | - | $31.00 K(-64.8%) | $90.85 M(+0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $88.00 K(-26.7%) | $90.13 M(-52.5%) |
| Dec 2021 | $189.67 M(>+9900.0%) | $120.00 K(-99.9%) | $189.67 M(+0.0%) |
| Sept 2021 | - | $90.61 M(<-9900.0%) | $189.59 M(+91.5%) |
| June 2021 | - | -$686.00 K(-100.7%) | $98.98 M(-0.7%) |
| Mar 2021 | - | $99.63 M(>+9900.0%) | $99.69 M(>+9900.0%) |
| Dec 2020 | $288.00 K(-99.2%) | - | - |
| Dec 2020 | - | $40.00 K(+3900.0%) | $288.00 K(+16.1%) |
| Sept 2020 | - | $1000.00(-96.2%) | $248.00 K(+0.4%) |
| June 2020 | - | $26.00 K(-88.2%) | $247.00 K(+11.8%) |
| Mar 2020 | - | $221.00 K | $221.00 K |
| Dec 2019 | $34.81 M | - | - |
FAQ
- What is TScan Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for TScan Therapeutics?
- What is TScan Therapeutics annual CFF year-on-year change?
- What is TScan Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for TScan Therapeutics?
- What is TScan Therapeutics quarterly CFF year-on-year change?
- What is TScan Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for TScan Therapeutics?
- What is TScan Therapeutics TTM CFF year-on-year change?
What is TScan Therapeutics annual cash flow from financing activities?
The current annual CFF of TCRX is $135.44 M
What is the all time high annual CFF for TScan Therapeutics?
TScan Therapeutics all-time high annual cash flow from financing activities is $189.67 M
What is TScan Therapeutics annual CFF year-on-year change?
Over the past year, TCRX annual cash flow from financing activities has changed by +$106.09 M (+361.38%)
What is TScan Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TCRX is $1.23 M
What is the all time high quarterly CFF for TScan Therapeutics?
TScan Therapeutics all-time high quarterly cash flow from financing activities is $161.59 M
What is TScan Therapeutics quarterly CFF year-on-year change?
Over the past year, TCRX quarterly cash flow from financing activities has changed by +$1.48 M (+588.10%)
What is TScan Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TCRX is $163.09 M
What is the all time high TTM CFF for TScan Therapeutics?
TScan Therapeutics all-time high TTM cash flow from financing activities is $189.67 M
What is TScan Therapeutics TTM CFF year-on-year change?
Over the past year, TCRX TTM cash flow from financing activities has changed by +$27.56 M (+20.34%)